The advent of tyrosine kinase inhibitors (TKIs) has radically altered the outcome of patients with chronic myeloid leukemia (CML). Patients with chronic-phase disease can now expect a 10-year survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results